Quality of Life in SMA Patients Under Treatment With Nusinersen

Background: Spinal Muscular Atrophy (SMA) is a severe neurodegenerative disease, characterized by progressive muscle weakness and atrophy. The approval of the antisense oligonucleotide (ASO) nusinersen now provides an effective pharmacological approach with the potential to slow down or stop disease...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Neurol
Main Authors: Mix, Lucas, Winter, Benedikt, Wurster, Claudia D., Platen, Sophia, Witzel, Simon, Uzelac, Zeljko, Graf, Heiko, Ludolph, Albert C., Lulé, Dorothée
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Neurology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8039289/
https://ncbi.nlm.nih.gov/pubmed/33854472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2021.626787
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados